Haptocure

Haptocure is a private Israeli biotech company focused on precision medicine approaches for patients with diabetes who carry specific haptoglobin genotypes associated with elevated cardiovascular risk. The company appears to have licensed intellectual property from Technion-related researchers around the use of haptoglobin genotyping and orally formulated d-alpha-tocopheryl acetate for genotype-selected diabetic populations. Its lead disclosed program is Haptilix, an oral small-molecule/vitamin-based product candidate aimed at metabolic and cardiovascular complications in diabetes. Public information suggests Haptocure remained an early-stage development company with limited disclosed pipeline breadth and no evidence of advanced clinical-stage commercialization. The company is also referenced in scientific disclosures through its ties to founders and advisors involved in haptoglobin research and diabetic cardiovascular risk stratification.